Uppsala, Sweden

Karin Wernersson

This inventor holds 1 USPTO granted patent. Top assignee: Cytiva Sweden Ab. Active years: 2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Karin Wernersson. Retrieved from https://idiyas.com/inventor/karin-wernersson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2021

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Karin Wernersson in Cell Culture Technology

Introduction

Karin Wernersson is a notable inventor based in Uppsala, Sweden. She has made significant contributions to the field of cell culture technology, particularly in the development of methods that enhance the production of clinically relevant cell products. Her work is crucial for advancements in cell therapy.

Latest Patents

Karin Wernersson holds a patent for a method titled "Semi-static cell culture." This invention relates to cell culture in bioreactors, specifically flexible cellbag bioreactors. The patent focuses on simplifying the production processes for cell products that are essential in therapeutic applications. She has 1 patent to her name.

Career Highlights

Karin is currently employed at Cytiva Sweden AB, where she continues to innovate in the field of biotechnology. Her work at Cytiva has positioned her as a key player in the development of advanced bioprocessing technologies.

Collaborations

Karin collaborates with talented professionals in her field, including Claudia Nune and Tanja Lovgren. These collaborations enhance the research and development efforts at Cytiva, fostering an environment of innovation.

Conclusion

Karin Wernersson's contributions to cell culture technology exemplify the impact of innovative thinking in biotechnology. Her patent and ongoing work at Cytiva Sweden AB highlight her commitment to advancing cell therapy solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…